ENGINEERING DE NOVO ANTITUMOR IMMUNITY USING PATIENT-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR)-MODIFIED T CELLS. DEVELOPMENT OF A NEW CLASS OF CARS EXPLOITING THE BROAD AND SELECTIVE GBM BINDING PROPERTIES OF THE SCORPION TOXIN PEPTIDE CHLOROTOXIN (CTX) AND EVALUATE THE POTENTIAL OF A CTX-CAR TO LIMIT GBM ANTIGEN ESCAPE.

PI: Christine E. Brown, PH.D.
Associate Director, T Cell Therapeutics Research Laboratory
Departments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology
City of Hope
Duarte, CA

Close Menu